tcrαβ+/cd19+ depleted allogeneic hematopoietic stem cell
Cell therapyexperimental
Clinical trial activity
5 trials · 4 clinical orgs · 0 marketing orgs
Phase 1
3
Phase 2
3
Phase 3
0
Phase 4
0
Earliest trial started Jan 1, 2016 (NCT02508038)
Timeline
Indications
Studied for
- Anemia, Sickle Cell · Phase 2
- Fanconi Anemia · Phase 1/Phase 2
- Hematologic Diseases · Phase 1
- Hematopoietic Stem Cell Transplantation · Phase 2
- Hodgkin Disease · Phase 1
- Leukemia, Myeloid, Acute · Phase 1
- Lymphoma, Non-Hodgkin · Phase 1
- Myelodysplastic Syndromes · Phase 1
- Myeloproliferative Disorders · Phase 1
- Neuroblastoma · Phase 1
- Neuroectodermal Tumors, Primitive · Phase 1
- Osteosarcoma · Phase 1
- Precursor Cell Lymphoblastic Leukemia-Lymphoma · Phase 1
- Rhabdomyosarcoma · Phase 1
- Sarcoma, Ewing · Phase 1
Mechanism of action
- Stem CellSupplementation
Stem Cell supplementation
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Also known as
- tcralphabeta+/cd19+ depleted haploidentical hsct
- tcrαβ+/cd19+ depleted haploidentical hsct
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT04806347 | Phase 1 | Mar 31, 2022 | University of Wisconsin |
| NCT04784052 | Phase 1/Phase 2 (Phase 2) | Oct 31, 2021 | Stanford University |
| NCT04201210 | Phase 2 | Apr 1, 2020 | University of Regensburg |
| NCT04088760 | Phase 2 | Sep 30, 2019 | University of Cincinnati |
| NCT02508038 | Phase 1 | Jan 1, 2016 | University of Wisconsin |
Showing 5 of 5 trials
Page 1 / 1
Organizations
Research & Development (4)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| University of Wisconsin | Academic/Hospital | 2 | 2 | 1 | 2016 |
| Stanford University | Academic/Hospital | 1 | 1 | 1 | 2021 |
| University of Cincinnati | Academic/Hospital | 1 | 1 | 1 | 2019 |
| University of Regensburg | Academic/Hospital | 1 | 1 | 1 | 2020 |
4 organizations
Page 1 / 1